Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 21Terminated 3Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Carboplatin 8Paclitaxel 7Taxes 6Cisplatin 6pembrolizumab 5Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Platinum 4Fluorouracil 4Capecitabine 41,2-diaminocyclohexaneplatinum II citrate 4Radiotherapy, Conformal 3Metformin 3Etoposide 3Doxorubicin 3Cyclophosphamide 3Brachytherapy 3folfirinox 2aumolertinib 2Radiotherapy 2Proton Therapy 2Prednisone 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Leucovorin 2Ifosfamide 2Gemcitabine 2Folfox protocol 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Has results × trifluridine tipiracil drug combination × Clear all
NCT03992456 2024-05-21

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Academic and Community Cancer Research United

Phase 2 Unknown
12 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡